Food
Date | Broker name | New | Price | Old price target | New price target | Broker change |
---|---|---|---|---|---|---|
20-Jul-22 | Barclays | Overweight | 97.50 | 137.00 | 137.00 | Reiteration |
21-Apr-22 | Barclays | Overweight | 100.95 | 136.00 | 136.00 | Reiteration |
17-Feb-22 | Barclays | Overweight | 109.80 | 135.00 | 136.00 | Reiteration |
02-Aug-21 | Barclays | Overweight | 128.35 | 133.00 | 135.00 | Reiteration |
01-Jul-21 | Barclays | Overweight | 119.00 | 131.00 | 133.00 | Reiteration |
10-Aug-12 | AlphaValue | Sell | - | - | - | DownGrade |
24-Feb-12 | AlphaValue | Reduce | - | - | - | DownGrade |
08-Aug-11 | AlphaValue | Add | - | - | - | Upgrade |
05-Aug-11 | Royal Bank of Scotland | Buy | - | - | - | Reiteration |
27-Apr-11 | AlphaValue | Reduce | - | - | - | DownGrade |
11-Mar-11 | AlphaValue | Add | - | - | - | Upgrade |
04-Mar-11 | AlphaValue | Reduce | - | - | - | DownGrade |
14-Feb-11 | JP Morgan Cazenove | Overweight | - | - | - | New Coverage |
08-Dec-10 | Collins Stewart | Buy | - | - | - | New Coverage |
09-Nov-10 | Evolution Securities | Add | - | - | - | DownGrade |
02-Sep-10 | Goldman Sachs | Neutral | - | - | - | DownGrade |
06-Jul-10 | Evolution Securities | Buy | - | - | - | New Coverage |
24-Nov-09 | Goldman Sachs | Buy | - | - | - | Reiteration |
17-Nov-09 | Societe Generale | Buy | - | - | - | New Coverage |
30-Oct-09 | Goldman Sachs | Buy | - | - | - | Reiteration |
Currency | Euro |
Share Price | 89.30 |
Change Today | -3.85 |
% Change | -4.13 % |
52 Week High | 95.2 |
52 Week Low | 71.7 |
Volume | 56,303 |
Shares Issued | 169.97m |
Market Cap | 15,178m |
RiskGrade | 121 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 3 |
Buy | 4 |
Neutral | 6 |
Sell | 0 |
Strong Sell | 0 |
Total | 13 |
Latest | Previous | |
---|---|---|
Interim | Final | |
Ex-Div | 10-Oct-24 | 11-Apr-24 |
Paid | 08-Nov-24 | 10-May-24 |
Amount | 38.10¢ | 80.80¢ |
Time | Volume / Share Price |
17:13 | 3,425 @ 91.49 |
17:12 | 351 @ 92.50 |
16:35 | 2 @ 89.30 |
16:35 | 2 @ 89.30 |
16:30 | 4,088 @ 91.50 |
Chair | Tom Moran |
CEO | Edmond Scanlon |
CFO | Marguerite Larkin |
You are here: research